Do you want to read an article? Please log in or register.
Lurbinectedin for extensive stage - small cell lung cancer (ES-SCLC): real world response patterns and survival outcomes
Lung, Respiratory and Thoracic Cancer
Related content
Lung, Respiratory and Thoracic Cancer
Second-line treatment outcomes after first-line chemotherapy plus immunotherapy in Extensive-Stage small cell lung cancer (ES-SCLC) patients: A large French multicenter study
Lung Cancer
Pons-Tostivint E, Ezzedine R, Goronflot T, Crequit P, Chatellier T, Raimbourg J, Bennouna J, Giroux Leprieur E, Porte M
doi: 10.1016/j.lungcan.2024.107887
Lung, Respiratory and Thoracic Cancer
Real-world outcomes of subsequent treatment strategies after durvalumab consolidation in stage III unresectable non-small cell lung cancer
Lung Cancer
Crespi V, Delcuratolo MD, Minuti G, Montrone M, Pilotto S, Roca E, Metro G, Leonetti A, Pelizzari G, Genova C, Olmetto E, Cortinovis D, Russo A, Pasello G, Bulotta A, Grossi F, Buosi R, Conte AD, Sini C, Greco C, Morabito A, Pignataro D, Pagano M, Gori S, Giannarelli D, Novello S, Passiglia F
doi: 10.1016/j.lungcan.2025.108576
Lung, Respiratory and Thoracic Cancer
Long-term outcome of chemoimmunotherapy for extensive-stage small-cell lung cancer according to key clinical trial eligibility: 3-year outcomes from a prospective cohort study
Lung Cancer
Sugisaka J, Fujimoto D, Tamiya M, Hata A, Matsumoto H, Yokoyama T, Taniguchi Y, Uchida J, Sato Y, Kijima T, Tanaka H, Furuya N, Masuda T, Sakata Y, Miyauchi E, Saito G, Miura S, Yamaguchi T, Daga H, Sakata S, Yamamoto N, Akamatsu H
doi: 10.1016/j.lungcan.2024.108056
Lung, Respiratory and Thoracic Cancer
Five-year survival in patients with extensive-stage small cell lung cancer treated with atezolizumab in the Phase III IMpower133 study and the Phase III IMbrella A extension study
Lung Cancer
Reck M, Dziadziuszko R, Sugawara S, Kao S, Hochmair M, Huemer F, de Castro G Jr, Havel L, Bernabé Caro R, Losonczy G, Lee JS, Kowalski DM, Andric Z, Califano R, Veatch A, Gerstner G, Batus M, Morris S, Kaul M, Cuchelkar V, Li H, Danner BJ, Nabet BY, Liu SV
doi: 10.1016/j.lungcan.2024.107924
RECOMMENDED
Lung, Respiratory and Thoracic Cancer
Real-world treatment and retreatment patterns and outcomes in patients with advanced or metastatic non-small cell lung cancer following nivolumab monotherapy in second line or later in France: an I-O Optimise analysis
★ 1
Recommended by
Dr Martin Frey, Faculty Member
Front Oncol
Justeau G, Chouaid C, Debieuvre D, Audigier-Valette C, Quantin X, Léna H, Bosquet L, Girard N, Schoemaker MJ, Mella M, Pinto Correia B, Rault C, Daumont MJ, Penrod JR, Lee A, Pérol M
doi: 10.3389/fonc.2025.1526931
Lung, Respiratory and Thoracic Cancer
Real-world overall survival after alternative dosing for pembrolizumab in the treatment of non-small cell lung cancer: A nationwide retrospective cohort study with a non-inferiority primary objective
Lung Cancer
Grit GF, van Geffen E, Malmberg R, van Leeuwen R, Böhringer S, Jm Smit H, Brocken P, Fh Eijsink J, Dronkers E, Gal P, Jaarsma E, Jhm van Drie-Pierik R, Mp Eldering-Heldens A, Machteld Wymenga AN, Gm Mol P, Zwaveling J, Hilarius D
doi: 10.1016/j.lungcan.2024.107950
Lung, Respiratory and Thoracic Cancer
Durvalumab after concurrent chemoradiotherapy for sensitizing epidermal growth factor receptor-mutant stage III non-small cell lung cancer: A Japanese Real-World data analysis
Lung Cancer
Fujisaki T, Miyauchi E, Kida G, Miura Y, Watanabe K, Ashinuma H, Tamiya M, Kikuchi H, Arai D, Takahashi S, Masuda K, Takigami A, Nagai Y, Miyawaki T, Tsubata Y, Nakao A, Masubuchi K, Nishiyama K, Watanabe S, Morita S, Maemondo M
doi: 10.1016/j.lungcan.2025.108597
Lung, Respiratory and Thoracic Cancer
Optimizing Treatment Strategies for Egfr-Mutated Non-Small-Cell Lung Cancer Treated with Osimertinib: Real-World Outcomes and Insights
Cancers (Basel)
Thomas QD, Girard N, Bosquet L, Cavaillon S, Filleron T, Eltaief S, Chouaid C, Lena H, Debieuvre D, Perol M, Quantin X
doi: 10.3390/cancers16213563
Lung, Respiratory and Thoracic Cancer
Real-world treatment and outcomes for EGFR WT advanced/metastatic non-squamous non-small cell lung cancer: pooled analysis from project LUMINATE-101
Oncologist
Girard N, Xu Q, Camidge DR, Baijal S, Ng S, Kamalakar R, Ratajczak C, Alhasani H, Crawford S, Karve S, Lu S
doi: 10.1093/oncolo/oyaf029